Overview
Regulatory agencies worldwide seek to reduce the impact of adverse events in financial and humanistic terms. We conduct post-authorisation safety studies (PASS) to investigate the frequency of already known adverse events and possible rare adverse events in a patient population that is typical of real-life users. ZEG Berlin, a Kantar Company, developed the EURAS/INAS study design, which has been internationally recognised as being scientifically and methodically robust.
Global scope
Key features
Robust methodology in risk/benefit assessment
We question participants directly at baseline and follow-ups, to spot co-variables you won't find anywhere else.
Regulatory acceptance
The EURAS/INAS study design is recognised as effective in risk assessment in the post-marketing environment.
Pioneering expertise
We have a proven record in global active safety surveillance and pharmacoepidemiology programs under the ENCePP seal.
